Celldex Therapeutics, Inc. (CLDX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 7 | 5 | 2 | 7 | 7 | 2 | - | 2 |
| Operating profit | $m | -287 | - | ||||||
| Net profit | $m | -60 | -71 | -112 | -141 | -158 | -259 | - | -272 |
| EPS reported | $ | -3.90 | - | ||||||
| Operating cashflow per share | $ | -3.17 | - | ||||||
| Capex per share | $ | 0.04 | - | ||||||
| FCF per share | $ | -3.21 | - | ||||||
| Free cash flow | $m | -214 | - | ||||||
| Net debt | $m | -519 | - | ||||||
| Book value equity | $m | 527 | - | ||||||
| Book value per share | $ | 7.93 | - | ||||||
| Number of shares | m | 66.5 | - | ||||||
| DPS (TTM paid) | $ | 0.00 | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.43 | - | ||||||
| P/S LTM | x | 1,204.09 | - | ||||||
| P/FCF LTM | x | -8.45 | - | ||||||
| EV/EBITDA LTM | x | -6.97 | - | ||||||
| EV/Sales LTM | x | 1,186.40 | - | ||||||
| Earnings Yield LTM | % | -14.33% | - | ||||||
| FCF Yield | % | -11.83% | - | ||||||
| Quality | |||||||||
| ROE | % | -49.09% | - | ||||||
| ROIC | % | -53.87% | - | ||||||
| Operating margin | % | -191.60% | - | ||||||
| Gross margin | % | +100.00% | - | ||||||
| FCF/Sales | % | -14243.9% | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -78.63% | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | - | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | - | ||||||
| FCF/Debt | x | -91.46 | - | ||||||
| Net Debt/EBITDA | x | 0.10 | - | ||||||
| EBIT/Net interest | x | 0.00 | - | ||||||
| Net debt/market cap | % | 0.00% | - | ||||||
| Net debt/Equity | x | -0.98 | - | ||||||
| Gross debt/equity | x | 0.00 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Celldex Therapeutics, Inc. (CLDX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free